Coherus Bio Sciences, Inc. CHRS
We take great care to ensure that the data presented and summarized in this overview for Coherus BioSciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CHRS
View all-
Black Rock Inc. New York, NY11.2MShares$21.5 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY10.4MShares$19.9 Million0.85% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$19.3 Million0.0% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U07.38MShares$14.1 Million0.1% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$5.8 Million0.31% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.74MShares$5.24 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.66MShares$5.09 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC2.43MShares$4.64 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.2MShares$4.21 Million0.0% of portfolio
-
Barclays PLC London, X02.07MShares$3.94 Million0.0% of portfolio
Latest Institutional Activity in CHRS
Top Purchases
Top Sells
About CHRS
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Insider Transactions at CHRS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 09
2024
|
Mats Wahlstrom |
BUY
Bona fide gift
|
Indirect |
99,988
+50.0%
|
-
|
|
Feb 09
2024
|
Mats Wahlstrom |
SELL
Bona fide gift
|
Direct |
99,988
-100.0%
|
-
|
|
Feb 01
2024
|
Mats Wahlstrom |
BUY
Exercise of conversion of derivative security
|
Direct |
59,988
+26.23%
|
$59,988
$1.67 P/Share
|
|
Jan 20
2024
|
Paul Reider Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,854
-5.64%
|
$9,708
$2.44 P/Share
|
|
Jan 20
2024
|
Dennis M Lanfear President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,218
-1.56%
|
$22,436
$2.44 P/Share
|
|
Jan 20
2024
|
Bryan J Mc Michael |
SELL
Payment of exercise price or tax liability
|
Direct |
1,707
-6.92%
|
$3,414
$2.44 P/Share
|
|
Jan 07
2024
|
Bryan J Mc Michael |
SELL
Payment of exercise price or tax liability
|
Direct |
1,707
-6.47%
|
$3,414
$2.87 P/Share
|
|
Jan 04
2024
|
Dennis M Lanfear President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,781
-1.61%
|
$23,562
$2.92 P/Share
|
|
Jan 04
2024
|
Paul Reider Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,275
-2.57%
|
$4,550
$2.92 P/Share
|
|
Dec 31
2023
|
Mc David Stilwell Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,440
-19.67%
|
$55,320
$3.33 P/Share
|
|
Dec 13
2023
|
Paul Reider Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,049
-2.27%
|
$4,098
$2.37 P/Share
|
|
Nov 22
2023
|
Dennis M Lanfear President & CEO |
SELL
Open market or private sale
|
Direct |
223,100
-23.37%
|
$446,200
$2.02 P/Share
|
|
Nov 22
2023
|
Dennis M Lanfear President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
299,940
+13.45%
|
$299,940
$1.42 P/Share
|
|
Apr 01
2023
|
Mc David Stilwell Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,457
-3.27%
|
$20,742
$6.84 P/Share
|
|
Apr 01
2023
|
Paul Reider Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,451
-2.74%
|
$14,706
$6.84 P/Share
|
|
Mar 31
2023
|
Vladimir Vexler Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
16,278
-12.27%
|
$97,668
$6.84 P/Share
|
|
Jan 20
2023
|
Dennis M Lanfear President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
86,250
+11.64%
|
-
|
|
Jan 20
2023
|
Mc David Stilwell Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+27.73%
|
-
|
|
Jan 20
2023
|
Vladimir Vexler Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+23.35%
|
-
|
|
Jan 20
2023
|
Bryan J Mc Michael |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+32.15%
|
-
|
Last 12 Months Summary
| Bona fide gift | 100K shares |
|---|---|
| Exercise of conversion of derivative security | 360K shares |
| Payment of exercise price or tax liability | 54K shares |
|---|---|
| Bona fide gift | 100K shares |
| Open market or private sale | 223K shares |